The immunogenicity and safety of a Hib-MenAC vaccine: a non-inferiority randomized, observer-blind trial in infants aged 3-5 months.

about

Adverse events following immunization with pentavalent vaccine: experiences of newly introduced vaccine in Iran.

P2860

Q38611378-EF197E02-8C3A-4B42-BDB7-DDB1BD54A52E

P2860

The immunogenicity and safety of a Hib-MenAC vaccine: a non-inferiority randomized, observer-blind trial in infants aged 3-5 months.

Item

http://www.wikidata.org/entity/Q40300059

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

The immunogenicity and safety ...... al in infants aged 3-5 months.

@en

type

Item

label

The immunogenicity and safety ...... al in infants aged 3-5 months.

@en

prefLabel

The immunogenicity and safety ...... al in infants aged 3-5 months.

@en

P1476

The immunogenicity and safety ...... al in infants aged 3-5 months.

@en

P2093

Feng-Cai Zhu

http://www.w3.org/2001/XMLSchema#string

Hong Tao

http://www.w3.org/2001/XMLSchema#string

Jian-Li Hu

http://www.w3.org/2001/XMLSchema#string

Jie Tang

http://www.w3.org/2001/XMLSchema#string

Jin-Fang Sun

http://www.w3.org/2001/XMLSchema#string

Jing-Xin Li

http://www.w3.org/2001/XMLSchema#string

Pei Liu

http://www.w3.org/2001/XMLSchema#string

Wei-Ming Dai

http://www.w3.org/2001/XMLSchema#string

Wen-Yu Liu

http://www.w3.org/2001/XMLSchema#string

Yu-Xiao Wang

http://www.w3.org/2001/XMLSchema#string

P2860

The Global Evolution of Meningococcal Epidemiology Following the Introduction of Meningococcal Vaccines

Meningococcal Vaccinations

Hib Vaccines: Past, Present, and Future Perspectives

Accelerating introduction of new vaccines: barriers to introduction and lessons learned from the recent Haemophilus influenzae type B vaccine experience

A systematic review and critical evaluation of invasive Haemophilus influenzae type B disease burden studies in Asia from the last decade: lessons learned for invasive bacterial disease surveillance.

Passive immunization against disease due to Haemophilus influenzae type b: concentrations of antibody to capsular polysaccharide in high-risk children.

Hospital surveillance of childhood bacterial meningitis in Senegal and the introduction of Haemophilus influenzae type b conjugate vaccine.

Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Safety and immunogenocity of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C-tetanus-toxoid conjugate vaccine in healthy Chinese children aged 6 months to 5 years old.

Bacterial meningitis and Haemophilus influenzae type b conjugate vaccine, Malawi.

P304

515-524

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14760584.2017.1303380

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-03-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28277801

http://www.w3.org/2001/XMLSchema#string

The immunogenicity and safety of a Hib-MenAC vaccine: a non-inferiority randomized, observer-blind trial in infants aged 3-5 months.

about

P2860

P2860

The immunogenicity and safety of a Hib-MenAC vaccine: a non-inferiority randomized, observer-blind trial in infants aged 3-5 months.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698